The Food and Drug Administration placed a clinical hold on Inovio Pharmaceuticals Inc.'s (Nasdaq: INO) Phase III program for VGX-3100. The stock price tumbled $1.37 to close at $6.99.
FDA places hold on Inovio's VGX-3100
October 24, 2016 at 17:52 PM EDT